1. United Kingdom Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Genus plc

Genus plc

GENSF
Genus plcUS flagOther OTC
31.07
USD
- -
- -
2.06BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
5.72
6.14
6.56
6.39
7.53
7.68
7.74
8.5
8.82
9.07
10.52
10.18
10.21
Basic EPS, GAAP
0.39
0.48
0.66
0.81
0.54
0.7
0.12
0.54
0.73
0.63
0.51
0.12
0.29
Free Cash Flow per Basic Share
0.26
0.42
0.33
0.19
0.26
0.34
0.08
0.47
0.52
-0.48
0.23
0.08
0.74
Dividend per Share
0.15
0.17
0.18
0.2
0.22
0.24
0.27
0.28
0.3
0.32
0.32
0.32
0.32
Book Value per Share
2.7
3.05
3.44
3.71
4.04
4.6
4.2
4.42
5.02
5.31
5.14
4.98
4.98
Tangible Book Value per Share
2.72
2.49
2.66
3.36
3.43
3.89
4.76
5.02
5.2
5.95
5.53
5.14
4.82
Basic Weighted Avg Shares
60
61
61
61
61
61
63
65
65
65
66
66
66
Sales/Revenue/Turnover
345
372
398
388
459
470
488
551
574
593
690
669
673
Operating Margin (%)
9.3
11.77
16.21
5.74
8.87
3
6.24
11.17
8.88
8.66
6.38
0.96
6.3
Depreciation Expense
11
12
13
15
20
24
28
37
35
39
44
47
45
Net Income, GAAP
23
29
40
49
33
43
8
35
47
41
33
8
19
Effective Tax Rate (%)
29.94
24.35
29.93
17.41
15.72
- -
32.32
22.89
16.13
24.17
19.29
56.36
- -
Profit Margin (%)
6.78
7.76
10.01
12.7
7.14
9.08
1.6
6.4
8.24
6.89
4.83
1.18
2.87
Working Capital
104
96
99
139
102
70
105
94
89
106
112
120
123
LT Debt
63
73
80
118
129
123
106
125
129
207
218
272
250
Total Equity
300
285
305
368
402
419
479
494
497
572
537
514
476
Return on Invested Capital (%)
6.08
8.72
11.52
4.08
6.57
- -
3.56
7.67
6.57
5.33
4.5
0.35
5.43
Return on Capital (%)
11.81
12.99
14.66
15.68
9.34
- -
2.94
9.49
11.24
9.39
8.15
3.83
6.56
Return on Common Equity (%)
15
16.62
20.28
22.71
13.91
16.18
2.85
12.78
15.4
12.13
9.74
2.38
5.89

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.95%
-0.44%
-7.3%
Free Cash Flow
90.35%
91.24%
852.94%
Net Income, GAAP
36.1%
13.98%
144.3%
Sales/Revenue/Turnover
5.61%
4.26%
0.6%
Total Cash Common Dividend
- -
- -
0.48%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
669
2025
- -
- -
- -
- -
673
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.12
2025
- -
- -
- -
- -
0.29
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.32
2025
- -
- -
- -
- -
0.32
2026
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Jorgen Kokke
Full Time Employees
3,500
Sector
Healthcare
Industry
Biotechnology
Address
Matrix House Basingstoke HM United Kingdom RG21 4DZ
IPO Date
Sep 11, 2009
Website
genusplc.com
Similar Companies
Solid Biosciences Inc. (SLDB)
Calidi Biotherapeutics, Inc. (CLDI)
Aptinyx Inc. (APTX)
Chimeric Therapeutics Limited (CHM.AX)
Vicapsys Life Sciences, Inc. (VICP)
Jupiter Neurosciences, Inc. (JUNS)
Business
Genus plc Genus plc develops and commercializes advanced animal genetics and biotechnology solutions for the global livestock industry, focusing on swine, dairy cattle and beef cattle to enhance productivity, sustainability and disease resistance. The company operates through two primary divisions, Genus PIC, which supplies genetically superior breeding pigs, porcine semen and technical services to pork producers; and Genus ABS, which provides bovine semen including sexed varieties, embryos from elite dairy and beef bulls, and associated advisory services to enable artificial insemination for improved milk yield, fertility and meat quality. Genus Research and Development supports these businesses with genomic selection, proprietary technologies such as sexed semen sorting and gene editing innovations like the PRRS-resistant pig, alongside comprehensive farmer support including data analytics and herd management advice; the company serves farmers and food producers across more than 85 countries on six continents through direct operations in 30 nations and distribution networks elsewhere. Founded as a predecessor entity in 1933 and incorporated in its current form in 1994, Genus plc maintains global headquarters in Basingstoke, United Kingdom, with key facilities including research laboratories in Madison, Wisconsin, USA, and major operational hubs in DeForest, Wisconsin, and Hendersonville, Tennessee. In recent strategic developments, Genus plc achieved U.S. Food and Drug Administration approval in April 2025 for its PRRS-resistant pig gene edit, advancing commercialization efforts in the U.S. and pursuing approvals in Canada, Mexico and Japan; the company completed Phase 2 of its ABS Value Acceleration Programme delivering annualized operating profit benefits of £10 million with Phase 3 initiatives targeting an additional £9 million; and in September 2025 announced accelerated formation of a porcine joint venture in China with Beijing Capital Agribusiness, under which BCA acquires 51% ownership for a gross cash payment of US$160 million plus US$7.5 million in milestones, with PIC China deconsolidated and Genus retaining 49% equity alongside intellectual property royalties on PRRS-resistant pig sales.

Company News

APIChatGPT